|Bid||0.00 x 1200|
|Ask||0.00 x 900|
|Day's range||7.64 - 7.94|
|52-week range||3.40 - 9.46|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||N/A|
|Earnings date||15 Nov 2021 - 19 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||24.92|
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can...
Senior leader with extensive global rare disease commercialization experienceTop-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the appointment of Theresa Heggie as Chief Commercial
Investors need to pay close attention to ProQR (PRQR) stock based on the movements in the options market lately.